Evolution of care in cirrhosis: Preventing hepatic decompensation through pharmacotherapy

doi:10.3748/wjg.v29.i1.61

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 29, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5761)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-1) series.

Item

Count

PDF

329

WORD

HTML

3136

Figures (1-2)

412

Tables (1-1)

305

Sum=4235

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

160

Download

403

Sum=563

Publishing Process of This Article

Item

Count

Browse

289

Download

674

Sum=963

Jan 7, 2023 (publication date) through Nov 19, 2024

Times Cited of This Article

Times Cited (10)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Jan 7, 2023; 29(1): 61-74
Published online Jan 7, 2023. doi: 10.3748/wjg.v29.i1.61

Open in New Tab Full Size Figure Download Figure

Figure 1 Management of cirrhosis in comparison to congestive heart failure. ACE: Angiotensin converting enzyme; ANRI: Angiotensin receptor-neprilysin inhibitor; ARB: Angiotensin receptor blocker; CSPH: Clinically-significant portal hypertension; GDMT: Guideline-directed medical therapy; HFrEF: Heart failure with reduced ejection fraction; LVAD: Left ventricular assist device; MRA: Mineralocorticoid receptor antagonist; NSBB: Non-selective beta-blocker; SGLT2: Sodium-glucose cotransporter 2; TIPS: Transjugular intrahepatic portosystemic shunting; TTE: Transthoracic echocardiogram.

Open in New Tab Full Size Figure Download Figure

Figure 2 Therapeutic targets in the prevention of hepatic decompensation. ACE: Angiotensin converting enzyme; ARB: Angiotensin receptor blocker; HRS: Hepatorenal syndrome; MRA: Mineralocorticoid receptor antagonist; NSBB: Non-selective beta-blocker; RAAS: Renin-angiotensin-aldosterone system; SBP: Spontaneous bacterial peritonitis; SGLT2: Sodium-glucose cotransporter 2.

Citation: Lee S, Saffo S. Evolution of care in cirrhosis: Preventing hepatic decompensation through pharmacotherapy. World J Gastroenterol 2023; 29(1): 61-74
URL: https://www.wjgnet.com/1007-9327/full/v29/i1/61.htm
DOI: https://dx.doi.org/10.3748/wjg.v29.i1.61